Zhang Qinguo, Tang Xuhua, Shen Jiang
Department of General Surgery, Zhuji Sixth People's Hospital Shaoxing, Zhejiang Province, China.
Department of General Surgery, Zhuji People's Hospital of Zhejiang Province Shaoxing, Zhejiang Province, China.
Am J Transl Res. 2021 Apr 15;13(4):3120-3128. eCollection 2021.
To explore the therapeutic effect of low-molecular-weight heparin calcium (LMWH-Ca) combined with Xueshuantong injections in treating elderly acute deep venous thrombosis (ADVT) patients, and to analyze the effect of this combination on the coagulation function, hemorheology, and safety.
A total of 122 elderly patients with ADVT who were treated in our hospital were recruited as the study cohort. The patients were randomly divided into a control group (n=61) and an observation group (n=61). The patients in the control group were given abdominal subcutaneous injections of low-molecular-weight heparin calcium (LMWH-Ca). The patients in the observation group were given intravenous drips of LMWH-Ca (low-molecular-weight heparin calcium) and Xueshuantong injections. After the treatment, comparisons of the detumescence times of the affected limb, the differences in the circumferences of the lower limbs, the coagulation parameters, the overall response rates, the incidences of complications, and the hemorheological parameters were conducted between both groups.
After the treatment, the detumescence times and the average differences in the circumferences of the lower limbs were significantly reduced (P<0.001; all P<0.001), the prothrombin times (PT) and the activated partial thromboplastin times (APTT) were significantly extended (all P<0.01), the overall response rate was higher (all P<0.05), and the three hemorheological parameters (high shear viscosity, low shear viscosity, and plasma viscosity) were lower in the observation group than they were in the control group (all P<0.001), there were no statistical differences in the fibrinogen (FIB) levels, the incidences of complications, or the incidences of adverse drug reactions between the two groups (P>0.05; P=0.343; P=0.298).
To sum up, low-molecular-weight heparin combined with Xueshuantong injections can effectively treat elderly ADVT patients, reduce the differences in the circumferences of the lower limbs, regulate the coagulation function, and improve the blood viscosity, so it is worthy of clinical promotion.
探讨低分子肝素钙联合血塞通注射液治疗老年急性深静脉血栓形成（ADVT）患者的疗效，并分析该联合用药对凝血功能、血液流变学及安全性的影响。
选取我院收治的122例老年ADVT患者作为研究队列。将患者随机分为对照组（n = 61）和观察组（n = 61）。对照组患者给予腹部皮下注射低分子肝素钙（LMWH-Ca）。观察组患者给予静脉滴注LMWH-Ca（低分子肝素钙）及血塞通注射液。治疗后，比较两组患肢消肿时间、下肢周径差值、凝血参数、总有效率、并发症发生率及血液流变学参数。
治疗后，患肢消肿时间及下肢周径平均差值均显著缩短（P < 0.001；所有P < 0.001），凝血酶原时间（PT）及活化部分凝血活酶时间（APTT）均显著延长（所有P < 0.01），总有效率更高（所有P < 0.05），观察组血液流变学三项参数（高切黏度、低切黏度及血浆黏度）低于对照组（所有P < 0.001），两组纤维蛋白原（FIB）水平、并发症发生率及药物不良反应发生率比较，差异均无统计学意义（P > 0.05；P = 0.343；P = 0.298）。
综上所述，低分子肝素联合血塞通注射液可有效治疗老年ADVT患者，减少下肢周径差值，调节凝血功能，改善血液黏度，值得临床推广。
